Literature DB >> 17920160

The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.

Lidia Glodzik-Sobanska1, Elizabeth Pirraglia, Miroslaw Brys, Susan de Santi, Lisa Mosconi, Kenneth E Rich, Remigiusz Switalski, Leslie Saint Louis, Martin J Sadowski, Frank Martiniuk, Pankaj Mehta, Domenico Pratico, Raymond P Zinkowski, Kaj Blennow, Mony J de Leon.   

Abstract

While cerebrospinal fluid (CSF) biomarkers are of use in the prediction and diagnosis of Alzheimer's disease our understanding of the background effects of age and the ApoE genotype is limited. Seventy-eight community-based normal volunteers (mean age 60+/-10 years, range 36-86) were examined to determine the relationships between CSF measures of total tau (T-tau), hyperphosphorylated tau (P-tau 231), amyloid beta (Abeta42/Abeta40 ratio), and isoprostane (IP) with age and ApoE genotype. The results showed that age by epsilon4 genotype interactions were found for P-tau231 (beta=1.82; p<0.05) and IP (beta=1.6; p<0.05). T-tau CSF concentration increased with age. The increasing CSF concentrations of P-tau and IP in epsilon4 carriers suggest that early tauopathy and oxidative stress may be related to the increased risk for AD. The data also suggest that T-tau changes are more age dependent than Abeta changes. The evidence that P-tau231 and IP are the earliest markers for the neuronal damage related to AD awaits longitudinal study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17920160      PMCID: PMC2774788          DOI: 10.1016/j.neurobiolaging.2007.08.019

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  61 in total

1.  Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.

Authors:  M Sjögren; H Vanderstichele; H Agren; O Zachrisson; M Edsbagge; C Wikkelsø; I Skoog; A Wallin; L O Wahlund; J Marcusson; K Nägga; N Andreasen; P Davidsson; E Vanmechelen; K Blennow
Journal:  Clin Chem       Date:  2001-10       Impact factor: 8.327

Review 2.  Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways.

Authors:  Xiongwei Zhu; Arun K Raina; Hyoung-Gon Lee; Mark Chao; Akihiko Nunomura; Massimo Tabaton; Robert B Petersen; George Perry; Mark A Smith
Journal:  Antioxid Redox Signal       Date:  2003-10       Impact factor: 8.401

3.  Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E.

Authors:  Raffaele De Caterina; Francesco Cipollone; Francesca Paola Filardo; Marco Zimarino; Walter Bernini; Guido Lazzerini; Tonino Bucciarelli; Angela Falco; Paola Marchesani; Raffaella Muraro; Andrea Mezzetti; Giovanni Ciabattoni
Journal:  Circulation       Date:  2002-11-12       Impact factor: 29.690

4.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

Authors:  Katharina Buerger; Raymond Zinkowski; Stefan J Teipel; Tero Tapiola; Hiroyuki Arai; Kaj Blennow; Niels Andreasen; Klaus Hofmann-Kiefer; John DeBernardis; Daniel Kerkman; Cheryl McCulloch; Russell Kohnken; Frank Padberg; Tuula Pirttilä; Marc B Schapiro; Stanley I Rapoport; Hans-Jürgen Möller; Peter Davies; Harald Hampel
Journal:  Arch Neurol       Date:  2002-08

5.  Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging.

Authors:  Henry Rusinek; Susan De Santi; Dina Frid; Wai-Hon Tsui; Chaim Y Tarshish; Antonio Convit; Mony J de Leon
Journal:  Radiology       Date:  2003-12       Impact factor: 11.105

6.  Neuropathology of cognitively normal elderly.

Authors:  D S Knopman; J E Parisi; A Salviati; M Floriach-Robert; B F Boeve; R J Ivnik; G E Smith; D W Dickson; K A Johnson; L E Petersen; W C McDonald; H Braak; R C Petersen
Journal:  J Neuropathol Exp Neurol       Date:  2003-11       Impact factor: 3.685

Review 7.  CSF phosphorylated tau--does it constitute an accurate biological test for Alzheimer's disease?

Authors:  Alex Mitchell; Nick Brindle
Journal:  Int J Geriatr Psychiatry       Date:  2003-05       Impact factor: 3.485

8.  Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study.

Authors:  Ara S Khachaturian; Christopher D Corcoran; Lawrence S Mayer; Peter P Zandi; John C S Breitner
Journal:  Arch Gen Psychiatry       Date:  2004-05

9.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

Authors:  Harald Hampel; Katharina Buerger; Raymond Zinkowski; Stefan J Teipel; Alexander Goernitz; Niels Andreasen; Magnus Sjoegren; John DeBernardis; Daniel Kerkman; Koichi Ishiguro; Hideto Ohno; Eugeen Vanmechelen; Hugo Vanderstichele; Cheryl McCulloch; Hans-Jurgen Moller; Peter Davies; Kaj Blennow
Journal:  Arch Gen Psychiatry       Date:  2004-01

Review 10.  CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.

Authors:  Kaj Blennow; Eugeen Vanmechelen
Journal:  Brain Res Bull       Date:  2003-08-15       Impact factor: 4.077

View more
  39 in total

1.  Interactive effects of physical activity and APOE-ε4 on BOLD semantic memory activation in healthy elders.

Authors:  J Carson Smith; Kristy A Nielson; John L Woodard; Michael Seidenberg; Sally Durgerian; Piero Antuono; Alissa M Butts; Nathan C Hantke; Melissa A Lancaster; Stephen M Rao
Journal:  Neuroimage       Date:  2010-08-05       Impact factor: 6.556

2.  Age and diagnostic performance of Alzheimer disease CSF biomarkers.

Authors:  N Mattsson; E Rosén; O Hansson; N Andreasen; L Parnetti; M Jonsson; S-K Herukka; W M van der Flier; M A Blankenstein; M Ewers; K Rich; E Kaiser; M M Verbeek; M Olde Rikkert; M Tsolaki; E Mulugeta; D Aarsland; P J Visser; J Schröder; J Marcusson; M de Leon; H Hampel; P Scheltens; A Wallin; M Eriksdotter-Jönhagen; L Minthon; B Winblad; K Blennow; H Zetterberg
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

3.  Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Authors:  Jon B Toledo; Henrik Zetterberg; Argonde C van Harten; Lidia Glodzik; Pablo Martinez-Lage; Luisella Bocchio-Chiavetto; Lorena Rami; Oskar Hansson; Reisa Sperling; Sebastiaan Engelborghs; Ricardo S Osorio; Hugo Vanderstichele; Manu Vandijck; Harald Hampel; Stefan Teipl; Abhay Moghekar; Marilyn Albert; William T Hu; Jose A Monge Argilés; Ana Gorostidi; Charlotte E Teunissen; Peter P De Deyn; Bradley T Hyman; Jose L Molinuevo; Giovanni B Frisoni; Gurutz Linazasoro; Mony J de Leon; Wiesje M van der Flier; Philip Scheltens; Kaj Blennow; Leslie M Shaw; John Q Trojanowski
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

4.  Soluble amyloid-β levels and late-life depression.

Authors:  Ricardo S Osorio; Tyler Gumb; Nunzio Pomara
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease.

Authors:  Jeremy Koppel; Fabien Campagne; Valérie Vingtdeux; Ute Dreses-Werringloer; Michael Ewers; Dan Rujescu; Harald Hampel; Marc L Gordon; Erica Christen; Julien Chapuis; Blaine S Greenwald; Peter Davies; Philippe Marambaud
Journal:  Mol Med       Date:  2011-05-24       Impact factor: 6.354

6.  Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers.

Authors:  Tessandra Stewart; Min Shi; Aanchal Mehrotra; Patrick Aro; David Soltys; Kathleen F Kerr; Cyrus P Zabetian; Elaine R Peskind; Peggy Taylor; Leslie M Shaw; John Q Trojanowski; Jing Zhang
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

7.  Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid.

Authors:  Simona Vuletic; Ge Li; Elaine R Peskind; Hal Kennedy; Santica M Marcovina; James B Leverenz; Eric C Petrie; Virginia M-Y Lee; Douglas Galasko; Gerard D Schellenberg; John J Albers
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

8.  Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.

Authors:  Anders M Fjell; Kristine B Walhovd; Christine Fennema-Notestine; Linda K McEvoy; Donald J Hagler; Dominic Holland; Kaj Blennow; James B Brewer; Anders M Dale
Journal:  Cereb Cortex       Date:  2010-01-04       Impact factor: 5.357

9.  Neuronal fiber bundle lengths in healthy adult carriers of the ApoE4 allele: a quantitative tractography DTI study.

Authors:  Lauren E Salminen; Peter R Schofield; Elizabeth M Lane; Jodi M Heaps; Kerrie D Pierce; Ryan Cabeen; David H Laidlaw; Erbil Akbudak; Thomas E Conturo; Stephen Correia; Robert H Paul
Journal:  Brain Imaging Behav       Date:  2013-09       Impact factor: 3.978

10.  Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies.

Authors:  Rachel Mistur; Lisa Mosconi; Susan De Santi; Marla Guzman; Yi Li; Wai Tsui; Mony J de Leon
Journal:  J Clin Neurol       Date:  2009-12-31       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.